Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350173 | 0.88 | ALOX5 (0.57) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL21605384 | 0.85 | ABL1 (0.42) | ALOX5ALDH1A1KMT2AMAPK1RECQL | |
| SCHEMBL14350198 | 0.85 | ALOX5 (0.53) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL14350184 | 0.84 | ALDH1A1 (0.54) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL14350196 | 0.84 | ALDH1A1 (0.54) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL14350199 | 0.84 | ALDH1A1 (0.54) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL21758682 | 0.82 | LTA4H (0.46) | ALOX5ALDH1A1KMT2ATDP1LTA4H | |
| SCHEMBL16906274 | 0.81 | ALOX5 (0.52) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL14350237 | 0.80 | SMN1; SMN2 (0.50) | ALOX5ALDH1A1KMT2AMAPK1TDP1 | |
| SCHEMBL1713228 | 0.80 | ALOX5 (0.63) | ALOX5ALDH1A1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. | 2024-12-26 | — | — | US | disclosed |
| EP-4466266-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| EP-3810613-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| US-20200339549-A1 | CXCR2 ANTAGONIST | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2020-10-29 | — | — | US | disclosed |
| EP-3185865-B1 | TETRAHYDRONAPTHTYRIDINE DERIVATIVES AS MGLUR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE. | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019244047-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244047-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-12-26 | — | — | WO | disclosed |
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. | 2018-09-11 | — | — | US | disclosed |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3185865-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016032921-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | ALOX5 326/4885ALDH1A1 760/4885KMT2A 1097/4885 |
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | GRIN2A, GRIN2C, GRIN2B | ALOX5 2773/4885ALDH1A1 4527/4885KMT2A 725/4885 |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | GRIN2A, GRIN2C, GRIN2B | ALOX5 2773/4885ALDH1A1 4527/4885KMT2A 725/4885 |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | ALOX5 4385/4885ALDH1A1 1472/4885KMT2A 1742/4885 |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | ALOX5 326/4885ALDH1A1 760/4885KMT2A 1097/4885 |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | TPMT, SARS1, NLN | ALOX5 4433/4885ALDH1A1 1075/4885KMT2A 1686/4885 |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR1A | ALOX5 584/4885ALDH1A1 659/4885KMT2A 225/4885 |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | ALOX5 4461/4885ALDH1A1 1592/4885KMT2A 2120/4885 |
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | ALOX5 1692/4885ALDH1A1 2158/4885KMT2A 2784/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | ALOX5 326/4885ALDH1A1 760/4885KMT2A 1097/4885 |
| US-20200339549-A1 | CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | ALOX5 1692/4885ALDH1A1 2158/4885KMT2A 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.